{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:16:11Z","timestamp":1783037771325,"version":"3.54.6"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cgh.2025.01.040","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:57:34Z","timestamp":1746737854000},"page":"1693-1694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concomitant Medications and Advanced Therapies in Ulcerative Colitis: Patient-centric Approach for Optimal Disease Control"],"prefix":"10.1016","volume":"23","author":[{"given":"Ferdinando","family":"D\u2019Amico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.01.040_bib1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41575-024-00989-y","article-title":"Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease","volume":"21","author":"Ma","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.040_bib2","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.cgh.2024.08.040","article-title":"No impact of concomitant medications on efficacy and safety of biologics and small molecules for ulcerative colitis","volume":"23","author":"Ahuja","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.040_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cgh.2023.09.011","article-title":"Washout periods in inflammatory bowel disease trials: a systematic literature review and proposed solutions","volume":"22","author":"Wils","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.040_bib4","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.040_bib5","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.cgh.2025.01.040_bib6","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn\u2019s disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.040_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.01.040_bib8","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1053\/j.gastro.2020.12.036","article-title":"Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis","volume":"160","author":"Wijnands","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.01.040_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cgh.2023.02.014","article-title":"Systematic review and meta-analysis: efficacy of mesalamine in irritable bowel syndrome","volume":"22","author":"Goodoory","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.040_bib10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/ecco-jcc\/jjad113","article-title":"Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in inflammatory bowel disease: post hoc analyses of clinical trial data","volume":"17","author":"Ungaro","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.01.040_bib11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO Guidelines on inflammatory bowel disease and malignancies","volume":"17","author":"Gordon","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.01.040_bib12","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.01.040_bib13","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1053\/j.gastro.2021.08.005","article-title":"Regular use of proton pump inhibitor and the risk of inflammatory bowel disease: pooled analysis of 3 prospective cohorts","volume":"161","author":"Xia","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.01.040_bib14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/ueg2.12069","article-title":"International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases","volume":"9","author":"D\u2019Amico","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2025.01.040_bib15","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S2468-1253(19)30089-5","article-title":"The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment","volume":"4","author":"Gracie","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.01.040_bib16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ueg2.12572","article-title":"Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-real-world evidence from the inflammatory bowel diseases-podcast study","volume":"12","author":"D\u2019Amico","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2025.01.040_bib17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.01.040_bib18","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.01.040_bib19","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.01.040_bib20","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2020.10.065","article-title":"Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD","volume":"160","author":"Le Berre","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525003362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525003362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:23:09Z","timestamp":1783034589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525003362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1542356525003362"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.01.040","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concomitant Medications and Advanced Therapies in Ulcerative Colitis: Patient-centric Approach for Optimal Disease Control","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2024.08.040","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute","name":"copyright","label":"Copyright"}]}}